Infant masking of recurrent hypoglycaemia and metabolic disease Authors: Bella Zhong, Michael Armarego, Nathan Dignam, Jye Gard Published: 2025 ABSTRACT SummaryHypoglycaemia is more common in childhood compared with adolescents and adults, as children have reduced ability to maintain glucose homeostasis. During illnesses, periods of fasting can accelerate a switch to ketosis. Thus, a presumptive misdiagnosis of recurrent hypoglycaemia due to accelerated starvation may be made due to cognitive biases.The diagnosis of other pathological causes of hypoglycaemia may be difficult and delayed. It is missed in up to 28% of cases. One confounder is a child’s ability to mask hypoglycaemia through altered feeding, such as frequent breastfeeding. The potential overlay from confounders must be closely considered in younger children presenting with hypoglycaemia.Keywords: Hypoglycemia, Congenital disorders, Infant health, Pediatrics, Metabolic disorders Background Hypoglycaemia in children >28 days old is defined as a blood glucose of <3.3 mmol/L (<60 mg/dL).1 Children have a poorer ability to maintain glucose homeostasis in times of fasting compared with adults.1 This is due to several key physiological differences, including smaller hepatic glycogen stores that are only able to meet a child’s glucose requirements for 6–12 hours, and lower muscle bulk that provides fewer gluconeogenic precursors to compensate in times of hypoglycaemia, resulting in a metabolism that is primed to more readily enter lipolysis and ketogenesis.2 Accelerated starvation (idiopathic ketotic hypoglycaemia) is relatively common and results in rapid-onset hypoglycaemia with ketonaemia and ketonuria early in a child’s illness.2 It is seen in children aged 18 months to 5 years and is a diagnosis of exclusion.2 Younger, smaller children with lower fasting capacity are at highest risk of recurrent episodes.3 There are many other pathological causes of hypoglycaemia related to impaired fasting capacity, including conditions associated with excess or inappropriate insulin production, deficiency of growth hormone or cortisol, disorders of the storage or release of glycogen, and disorders associated with impaired gluconeogenesis (eg, amino acid disorders and organic acid disorders). Other causes of hypoglycaemia include systemic conditions such as sepsis, shock or organ failure; liver disease; and medication or toxin exposure including alcohol.2 Collection of critical blood and urine samples at the time of hypoglycaemia is crucial for diagnosing many of these conditions, yet this may be missed when treatment of a severely hypoglycaemic child is prioritised during an acute event. Retrospective studies suggest the rate of undiagnosed endocrine or metabolic disorders in paediatric patients with recurrent hypoglycaemia is as high as 8–28%.4,6 One contributor to the rates of underdiagnosis is the differing pattern of oral intake in children. Frequent feeding, particularly in infants taking breastmilk or bottles, can mask abnormalities in normal glycaemic control.1 Thus, glucose homeostasis abnormalities may only be unmasked once a child begins to establish a more mature feeding pattern (ie, set mealtimes with larger windows of fasting) or when unwell with an illness in which there is a greater metabolic demand or impaired ability to feed as effectively. Case presentation A toddler arrived via ambulance to an emergency department (ED) following a 15 min seizure at home. On paramedic arrival, the seizure was rapidly terminated with intramuscular midazolam. A point-of-care blood sugar level (BSL) was unrecordable. After receiving 0.5 mg of intramuscular glucagon, then 15 g of oral glucose gel (15% concentration) 23 min later, the BSL was improved to a recordable level of 1.6 mmol/L. On arrival to the ED, the toddler was alert and distressed, and a repeat BSL showed a reading of 1.3 mmol/L. An intravenous 2 mL/kg 10% dextrose bolus was administered; 30 min later, BSL had improved to 6.4 mmol/L with ketones of 1.1 mmol/L. There was no history of intercurrent illness or prolonged fasting. However, the toddler’s parents described three previous events concerning possible seizures, which had resolved within minutes at home without intervention. These previous episodes occurred in the context of two routine vaccinations and the other when unwell with otitis media. Initial weight was on the 83rd percentile (Z=0.95) and length on the 8th percentile (Z=−1.41) for age. Examination revealed abdominal distension and massive hepatomegaly with the liver edge palpable below the level of the umbilicus. There were also clusters of non-tender papules and pustules of the palms, mouth and soles consistent with hand, foot and mouth disease. The toddler’s medical history was significant for hepatomegaly. He initially presented to a different hospital 2 months prior with elevated liver enzymes, in particular alanine aminotransferase and aspartate aminotransferase, found when investigating several months’ history of abdominal distension. During this admission, infectious and metabolic causes of hepatitis were investigated (table 1), with advice from the metabolic medicine service. Apart from cytomegalovirus serology showing positive immunoglobulin M (IgM) and IgG levels consistent with recent infection or reactivation, all other tests returned normal results. An ultrasound showed a heterogeneously hyperechoic liver measuring 15 cm. Table 1Metabolic investigations pursued during a previous hospitalisation for hepatomegalyInvestigationResult (reference range)InterpretationVery long-chain fatty acidsPristanate FA 1.48 μmol/L (0–2.5)Phytanate FA 11.3 μmol/L (0–20.0)C24/C22 ratio 0.833 ratio (0.550–1.050)C26/C22 ratio 0.017 ratio (0.000–0.030)NormalUrine oligosaccharidesHeavily stained oligosaccharide pattern that does not correspond to a recognised storage disorder profileNon-diagnostic patternN-palmitoyl-O-phosphocholineserine (lysosphingomyelin-509)<0.32 μmol/L (<0.32)NormalAlpha-glucosidase activity on dried blood spot (Pompe/GSD type II testing)7.3 pmol/spot/hour (2.5–25.4)NormalMucopolysaccharides screenNo abnormality detectedNormalLysosomal enzyme panelNormalNormalUric acid0.20 mmol/L (0.13–0.39)NormalLiver function testsALP 342 U/L (120–450)GGT 243 U/L (5–50)AST 1484 U/L (20–60)ALT 1374 U/L (5–40)HighBilirubin 7 μmol/L (0–20)Albumin 37 g/L (32–47)NormalLipid profileCholesterol 4.20 mmol/L (0–5.5)Triglyceride 3.2 mmol/L (0–2.0)HDL cholesterol 0.7 mmol/L (>1)LDL cholesterol 2.1 mmol/L (0–3.0)LDL/HDL ratio 3.2 ratio (<4.5)Mildly elevated triglyceridesCoagulation profileINR 1 ratio (0.8–1.2)APTT 31 s (22–32)Fibrinogen 3.9 g/L (1.5–4.0)NormalLactate2.1 mmol/L (0.5–2.0)Mildly elevatedUrine metabolic screenHex4+Na+++Nex5+Na+Possible GSD type II (Pompe disease)AST, aspartate aminotransferase; FA, Fatty Acid; GSD, glycogen storage disorder; HDL, high-density lipoprotein; LDL, low-density lipoprotein. Metabolic investigations pursued during a previous hospitalisation for hepatomegaly AST, aspartate aminotransferase; FA, Fatty Acid; GSD, glycogen storage disorder; HDL, high-density lipoprotein; LDL, low-density lipoprotein. The toddler was subsequently discharged with paediatric gastroenterology follow-up for further investigation of his hepatomegaly, the next plan being for genetic testing. Both of the toddlers’ parents were of Ashkenazi Jewish heritage. There was no extended family history of multiple miscarriages, poor growth or developmental delays. He had been reviewed and discharged from the metabolic medicine clinic prior to genetic testing. Investigations Results of the investigations performed at the time of ED presentation (table 2) demonstrated appropriate cortisol, growth hormone and insulin responses to hypoglycaemia. Table 2Extended hypoglycaemia investigationsInvestigationResult (reference range)InterpretationGlucose2.4 mmol/L (3.0–8.0)Low3-Hydroxybutyrate (ketones)1.41 mmol/L (<1.00)HighVenous blood gaspH 7.36 (7.35–7.45)pCO2 41 mm Hg (35–50)Bicarbonate 23 mmol/L (22–28)Normal acid baseCortisol889 nmol/L (100–440)HighGrowth hormone22 mU/L (2–45)NormalInsulin<0.5 mU/L (fasting 6–20)LowLactate1.2 mmol/L (1.0–1.8)NormalAmmonia30 μmol/L (<50)NormalAcylcarnitineNormal profileNormalAmino acidsGlutamine 213 μmol/L (300–850)Methionine 7 μmol/L (10–50)Proline 80 μmol/L (90–400)Threonine 32 μmol/L (60–280)Some low amino acids possibly due to intakeElectrolytesSodium 138 mmol/L (135–145)Potassium 5 mmol/L (3.5–5.0)Chloride 104 mmol/L (98–110)Bicarbonate 23 mmol/L (22–30)Urea 5.4 mmol/L (1.3–6.6)Creatinine 20 μmol/L (10–50)NormalLiver function testsALT 743 U/L (5–40)GGT 137 U/L (5–50)ALP 237 U/L (120–450)Bilirubin 6 μmol/L (0–20)Albumin 46 g/L (32–47)HighFree fatty acids0.58 mmol/L (0.00–0.71)NormalALP, Alkaline Phosphotase; ALT, alanine aminotransferase; aPTT, Activated Partial Thomboplastin Time; GGT, Gamma-glutmayl Transferase; INR, International Normalised Ratio. Extended hypoglycaemia investigations ALP, Alkaline Phosphotase; ALT, alanine aminotransferase; aPTT, Activated Partial Thomboplastin Time; GGT, Gamma-glutmayl Transferase; INR, International Normalised Ratio. A key differential diagnosis was of glycogen storage disorder (GSD), with GSD type IIIb subsequently diagnosed on genetic testing (table 3). The patient had three heterozygous pathogenic variants to the AGL gene: an intron, a frameshift and a missense variant. Table 3Metabolic disorder genetic testingResultsSignificanceHeterozygous for AGL c.4260-12A>GPathogenic for GSD IIIHeterozygous for AGL c.4456del, p.(Ser1486Profs*18)Pathogenic for GSD IIIHeterozygous for AGL c.1078C>T, p.(His360Tyr)Likely pathogenic—predominantly reported as homozygous in patients with GSD IIIGSD, glycogen storage disorder. Metabolic disorder genetic testing GSD, glycogen storage disorder. Treatment Management focused on rapidly correcting hypoglycaemia, calculating glucose requirements and trialling different strategies for sustaining normoglycaemia in an out-of-hospital environment. Initial treatment Normoglycaemia was initially maintained through the support of intravenous fluid support with 5% dextrose to supplement dietary glucose intake while the toddler was unwell. Initially, strategies to achieve normoglycaemia via dietary means were trialled. This included the consumption of 10 g Glycosade (modified cornstarch product, recommended from 2 years of age) before periods of expected fasting (eg, prior to bedtime) to act as a long-acting carbohydrate. Frequent BSL monitoring and detailed dietary and activity records over several weeks were used, aiming to devise a regimen tailored to the child’s glucose requirements. Stepwise management Unfortunately, the child experienced frequent overnight hypoglycaemic events despite many modified dietary regimens. Thus, ultimately the child required the additional support of overnight continuous nasogastric feeding with Poly-Joule (maltodextrin-based carbohydrate supplement) and Beneprotein (whey protein powder) to sustain normoglycaemia enterally. Follow-up The child was transferred to a hospital-at-home service for ongoing monitoring and dietitian support. Several hypoglycaemic events occurred over the following weeks, and further changes to the dietary plan were required, including additional supplementation with daytime nasogastric boluses of Glucerna (high-protein, low-glycaemic index feed), as well as the introduction of Beneprotein and Glycosade when the child reached over 2 years of age. Periods of fasting were difficult to maintain, with the child’s high weight for age (figure 1) reflecting his highly frequent oral feeding in response to unmeasured hypoglycaemia prior to diagnosis. Weight-for-length percentiles. Outcome and follow-up The toddler’s dietary plan and glucose requirements remained dynamic, and regular reviews with a specialist dietitian were vital. He now has a continuous glucose monitor to assist the family with detecting and treating asymptomatic hypoglycaemic events. The infant and family continue to work with the metabolic medicine team to optimise dietary plans, feeding behaviours and nutrition. Discussion GSD III is usually inherited in an autosomal recessive manner and presents as one of two phenotypes: type IIIa (85% of cases) with both liver and muscle glycogen stores affected and type IIIb (15% of cases) with isolated liver involvement.7 Hepatomegaly develops in early infancy, and those with type IIIa also develop myopathy, with mild to moderate hypotonia in infancy and progressive myopathy of distal muscle groups (calves, kyphoscoliosis, genu valgum and foot deformities) that are often insidious and detected in the third decade of life.8 Importantly, signs of left-sided heart failure from hypertrophic cardiomyopathy may also be detected in early adulthood. Most cases are detected in infancy on the discovery of hepatomegaly and poor growth with short stature due to chronic hypoglycaemia. Children with type IIIa are also usually detected from motor delays, exercise intolerance and raised creatine kinase due to myopathy.9 Later complications include increased risk of hyperlipidaemia (from a high-energy diet), liver cirrhosis, hepatic adenomas (7% of cases), osteopenia and osteoporosis (from malnutrition and reduced activity), type 2 diabetes mellitus and severe cardiac dysfunction.10 The initial treatment for GSD III centres around dietary measures to prevent hypoglycaemia through small, frequent feeds and avoiding fasting. This is balanced with the avoidance of excessive carbohydrate intake, through using a high-protein diet and low-glycaemic index carbohydrates, such as cornstarch and complex carbohydrates.7 11 In the longer term, patients should be monitored for growth and complications, with individualised multidisciplinary care as directed by their disease manifestations. Medicines that affect glucose metabolism (steroids, beta blockers) or can cause rhabdomyolysis (statins for hyperlipidaemia) should not be taken. Family planning and prenatal testing should also be offered.7 This case reflects a rare diagnosis, which illustrates the bias towards the familiar that often delays identification of a pathological cause for hypoglycaemia. There was a further overlay of authority bias, where pursuing an underlying metabolic cause for the patient’s presentation was deprioritised based on previous consultation and discharge from the metabolic medicine team. While rare disorders can often be misdiagnosed, the delayed diagnosis in this case exposed the child further to the risks of severe hypoglycaemia, such as seizures and neurological sequelae. As children with GSD may ‘self-medicate’ by increasing the volume and frequency of their intake of dietary glucose, the assessment of a child with hepatomegaly and hypoglycaemia should include a comprehensive dietary intake history. In a child with recurrent hypoglycaemia—which may be reflected in a history of frequent overnight feeds inconsistent with age, waking up with symptoms such as irritability, lethargy or hypotonia, and resolution of such symptoms after carbohydrate consumption—a high index of suspicion should be maintained. Presumptive diagnoses, such as accelerated starvation, should be cautiously debated. Patient’s perspective This was an extremely confusing and stressful time for us. It is interesting to note that our son had low blood sugar at birth, which doctors assigned to his large weight at birth. From birth he was a very squirmy, quite fussy baby. His seizure events were always in the middle of the night. Every morning he would wake extremely irritable until he ate breakfast, which he always devoured. If he was ever unwell and lacked an appetite. He was very fatigued; he would lay down on the floor a lot. This was noted by his daycare staff. When we received his diagnosis, we really tried to make the oral feeding of the cornstarch at night work. It was not working, and we were heartbroken to make the decision to give him the nasogastric tube, although we understood why it was necessary. We initially attempted to only use the enteral feeding at night and keep to a regular oral intake with food during the day to keep things as ‘normal’ as possible. However, it really did not work out, as we would constantly be obsessing and stressing over his meals and routine, and every meal would become a battle. When we moved to bolus feeds in the day, this is where we saw a great improvement in his BSL and overall health. Especially when using the ‘Glucerna Select’ formula over the regular Glucerna formula. We did appreciate how the hospital made us feel that we were making the decisions along the way and allowed us to trial different approaches ourselves. Our son has had the NG tube for around 5 months. He has a continuous feed at night via a pump (which comes with its own challenges) and feeds 2.5 hourly in the day. It’s been quite challenging for us and has definitely changed our lives. Learning points Infants and preschool-aged children are at higher risk of hypoglycaemic events when unwell due to their unique physiology and change in feeding patterns. Infants and preschool-aged children are at higher risk of hypoglycaemic events when unwell due to their unique physiology and change in feeding patterns. Due to the frequency of physiological hypoglycaemia in these age groups, other pathological causes of hypoglycaemia are often unrecognised and diagnosis may be delayed. Due to the frequency of physiological hypoglycaemia in these age groups, other pathological causes of hypoglycaemia are often unrecognised and diagnosis may be delayed. Children with glycogen storage disorders (GSD) develop hepatomegaly in early infancy, usually associated with poor growth and recurrent symptomatic hypoglycaemia. Children with glycogen storage disorders (GSD) develop hepatomegaly in early infancy, usually associated with poor growth and recurrent symptomatic hypoglycaemia. Given the frequency of infant feeding, children with GSD may mask their symptoms by overfeeding practices. Given the frequency of infant feeding, children with GSD may mask their symptoms by overfeeding practices. Multiorgan sequelae from GSD may be mitigated if diagnosis occurs in early childhood and the child is able to comply with a diet regimen that uses both supplementary glucose sources and careful avoidance of excessive carbohydrate ingestion. Multiorgan sequelae from GSD may be mitigated if diagnosis occurs in early childhood and the child is able to comply with a diet regimen that uses both supplementary glucose sources and careful avoidance of excessive carbohydrate ingestion. Footnotes Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy. Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Consent obtained from parent(s)/guardian(s) References